Publications by authors named "Matthias Reule"

Claim this Profile
C
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Matthias Reule

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Matthias Reule

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Brent Graham, Jayne Curry, Tomoko Smyth, Lynsey Fazal, Ruth Feltell, Matthias Reule

Cancer Sci· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Ruriko Tanaka, Matthew S Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Matthias Reule

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, Simon P Heaton, Mike I Walton, Matthias Reule

Mol Cancer Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Jayne Curry, Hayley Angove, Lynsey Fazal, John Lyons, Matthias Reule

Cell Cycle· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Steven Howard, Valerio Berdini, John A Boulstridge, Maria G Carr, David M Cross, Matthias Reule

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
Paul G Wyatt, Andrew J Woodhead, Valerio Berdini, John A Boulstridge, Maria G Carr, Matthias Reule

J Med Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.
Grit Kasper, Matthias Reule, Miriam Tschirschmann, Niels Dankert, Karen Stout-Weider

BMC Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis